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Advisory Professor: Paul Scheet Ph.D.

Deviations from a diploid configuration of the human genome, spanning
single genes or entire chromosomes, can have wide-ranging impacts on the variation of human phenotypes, including Mendelian and complex forms of diseases.
These chromosomal alterations - such as duplications, deletions or copy-neutral
loss-of-heterozygosity - are thus important forms of genetic variation for phenotyping populations of individuals as well as populations of cells. Indeed, copy
number variants (CNVs) serve as hallmarks of critical changes in the development of particular diseases such as cancer and thus may be used as biomarkers.
These CNVs may be either inherited (transmitted by germ cells, originating in
meiosis; “germline”) or acquired (originating in mitosis; “somatic mosaicism”).
The complex structure and the diverse mechanisms generating CNVs have been
studied molecularly, but this has generally not been attempted using population
data. This dissertation seeks to provide insights into CNV diversity in two complementary settings: 1) the genesis of germline copy number duplications, and 2)
the diversity of acquired CNVs within distinct tumor tissues. First, we develop a
novel method to disentangle the haplotype (the specific alleles on an inherited
chromosome) composition of de novo germline duplications to characterize the
“grandparental origin” of the extra piece of a chromosome. Using family-based
v

genome-wide association study data, we report a nearly 1-to-1 ratio of “bi-allelic”
duplications, likely arising from inter-chromatid non-allelic homologous recombination (NAHR), to “tri-allelic” duplications, from inter-chromosomal NAHR. In
addition, our method reveals a novel configuration, consisting of both tri-allelic
and bi-allelic duplications, which we hypothesize generated from spontaneous
inter-chromosomal and inter-chromatid NAHR. The rate of these “complex” duplications among all the de novo duplications is 6% in our analyses. Second, we
assess tumor heterogeneity of biphasic uterine carcinosarcoma (UCS) from 10 patients by analyzing the data of component-specific tumor samples (carcinomatous,
sarcomatous, and normal uterine tissues), generated from multiple platforms (SNP
array, DNA target sequencing, and whole transcriptome sequencing). We augment
the quantification of tumor heterogeneity by considering the haplotype information within the somatic copy number alterations for each sample to more precisely
annotate recurrent mutations. Our results imply that the carcinomatous and the
sarcomatous components in UCS originate from the same clone and the heterogeneity reflects relatively advanced stages. Overall, this dissertation shows the
potential utility of incorporating haplotype information in particular settings in
population science and cancer biology.
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Chapter 1
Introduction

1.1
1.1.1

Background
Genetic variation
Deoxyribonucleic acid (DNA) is the fundamental carrier of genetic informa-

tion encoded by four nucleotide bases (cytosine [C], guanine [G], adenine [A] or
thymine [T]). The long stretch of DNA coils to form chromosomes, the structural
units that segregate in the population. A human’s genome is diploid, with one
haploid genome inherited from paternal and one from maternal. Together, these
form 23 pairs of chromosomes consisting of 22 pairs of autosomes and a pair of sex
chromosomes being either XX (female) or XY (male). The chromosomes in each
pair are termed homologous chromosomes.
Any two haploid human genomes have 99.9% similarity. Genomic variation is the DNA differences among individuals. These variations are shaped by
acquired and germline mutations in the lifetime of individuals or propagating
through generations, including point mutations, copy number variations (CNVs),
and other chromosomal rearrangements (translocation, inversion, etc.).
An allele could be a variant form of a single nucleotide base, a gene, or a
stretch of DNA. If we sample a thousand human genomes together (or 2,000 haploid genomes), at a specific genomic location (locus) the nucleotide C may appear
200 times and the nucleotide T 1,800 times. We describe the estimated minor al200
), with the reference allele as T
lele frequency (MAF) at this locus is 10% ( 1800+200

and the alternative allele as C. A single nucleotide polymorphism (SNP) denotes a
1

common variant, generally with MAF greater than 1% or 0.5%.

1.1.2

Linkage disequilibrium and haplotypes
The non-random distribution of the MAFs at two loci in a population is

termed linkage disequilibrium (LD). Within a human genome the two alleles at
each locus could be A, C, G, or T; or could be arbitrarily labeled as “A” allele
(reference allele) and “B” allele (alternative allele). The concept of reference and
alternative alleles are in the population level while within individuals the terms
are interchangeable. A haplotype is a specific combination of alleles on a chromosome. For example, assuming there is a haplotype ACT in the specified genomic
locations 1, 2, and 3, when allele A is observed at the locus 1 in a chromosome, we
will know that allele C and T are at the locus 2 and 3 in the same chromosome.
When a consecutive order of alleles present in the same haplotype, those alleles
are in LD. The structural dependency between alleles within a haplotype is stable
which is valuable in many studies such as population stratification, genetic testing,
and evolution studies.

1.1.3

Meiosis
Meiosis is a type of cell divisions and a necessary step for reproductive pro-

cess in human. The number of chromosomes in the human gamete cells (egg or
sperm cells) reduces to half as one haploid genome per cell. There are two cycles
of cell division in meiosis. Meiosis I is the process where the DNA is replicated
and the daughter cells will have the same amount of DNA. After replication, each
chromosome will have two identical copies, called sister chromatid. Meiosis II is
the process where the amount of DNA is reduced to half and generate the final
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products, the haploid gamete cells. Homologous recombination (HR) guarantees
the unique genetic combination in each individual by exchanging DNA pieces between homologous chromosomes during meiosis.

1.1.4

Copy number variations
Copy number variations (CNVs) in a human genome are defined as the

copy number gains or losses of a stretch of DNA compared to the normal copy
number two. The length of a CNV can range from 1kb to the entire chromosome
(trisomy and monosomy) [1]. It sometimes refers to copy number alteration (CNA)
in the context of somatic changes of the gene copy number, mostly in the study of
cancer. It sometimes also refers to copy number polymorphism (CNP) if a CNV
exists in more than 1% of the population. Here in this thesis, we use the term CNV
without any implication of relative frequency or phenotypic effect. CNVs, together
with copy-neutral loss-of-heterozygosity (cn-LOH), are named allelic imbalance
(AI) in most of the studies.
A CNV can be inherited, or acquired. An inherited CNV indicates that the
change in the chromosome is transmitted from the parents, in which the parent
will also have the same CNV in most of the cases. An acquired CNV is a CNV
occurs at some time during a person’s life and typically presents only in a portion
of the cells (somatic mosaicism). Acquired mutation cannot be passed to next generation (unless it is in the germ cells). De novo means “new”, thus a de novo CNV
indicates the CNV is seen in the offspring but not in the parents. If a CNV occurs
in a person’s egg or sperm cells before or during meiosis and is transmitted to the
offspring, the offspring carries an inherited de novo CNV, which we often refer as
a germline-transmitted de novo CNV. If a CNV occurs in the fertilized egg shortly
after the egg and the sperm cells united and thus the growing embryo from this
3

fertilized egg carries such mutation in all (or most of) its cells, it is an acquired
de novo CNV. Sometimes it is hard to tell exactly when a de novo CNV arise, i.e.,
distinguish a germline-transmitted de novo CNV from an acquired de novo CNV.

1.1.5

CNVs genesis mechanisms and classification
CNVs in general can be considered as “mistakes” during cell division or

replication, either in meiosis or in mitosis. There are two major mechanisms responsible for the genesis of CNVs, (1) Crossing over between repetitive DNA,
caused by the underlying genome architecture; and (2) DNA breakage and rejoining, normally triggered by environmental stimulation such as ionizing radiation
[2].
The first mechanism refers to non-allelic homologous recombination (NAHR),
which results in a duplication and a reciprocal deletion by misalignment of the
highly identical DNA pieces dispersed in different locations of the chromosome
(mostly within the same chromosome). These identical DNA pieces, called segmental duplications (SDs), which have the following characteristics: (1) size ranges
from 1kb to 400 kb; (2) sequence similarity is larger than 90%; (3) located at multiple regions of the genome [3]. Because the SDs cluster within specific regions, and
the recombination occurs between any two SDs can be considered as the combination of a selection in a finite set. The complete sets of NAHR-derived CNVs are
essentially identical even between unrelated individuals [4]. Therefore this type
of CNVs is also called recurrent CNV. Note that NAHR appears to overwhelmingly occur during meiosis, although some rare exception are observed in mitosis
[5, 6, 7, 8]. Most recurrent CNVs are germline transmitted de novo.
The second mechanism can arise from several different mechanisms, such
as non-homologous end joining (NHEJ) and fork stalling and template switching
4

(FoSTeS) [9]. It happens when the DNA double strand breaks (DSB) repair mechanism rejoin the two mismatched breakpoints of the chromosome, which is usually
mediated by non-homology-based or microhomology-based [10] mechanisms. In
contrast, the CNV in this category are called nonrecurrent CNV. Because the breakpoints in the nonrecurrent CNVs are unique to themselves and, it is unlikely for
them to have exactly the same breakpoints even for some CNV regions shared
between unrelated individuals. Many somatic CNVs are nonrecurrent.

1.1.6

SNP microarray
SNP microarray is one of the first generation high-throughput technology

to perform a genome-wide scan of the genotype information at the designated loci
(SNPs typically) by utilizing DNA hybridization and fluorescence microscopy. The
output is the light signal with its intensity indicating the abundance of the allele in
the predetermined genomic locations. Then the light signals is transcribed by computational software into the genotype data; B allele frequency (BAF) represents the
proportion of B allele at each locus of a human genome, and log R ratio (LRR) represents the total intensity of both alleles compare to the background. At a normal
locus, the theoretical BAF could be 0, 0.5, or 1 for genotypes AA, AB, or BB, and
the theoretical LRR will be 0 (base 2 log of the copy number 2). Table 1.1 gives the
theoretical values of BAFs and LRRs at different AI regions.
CNV type

deletion (one copy)

BAF

0(A), 1(B)

LRR

log2 (1/2) = −1

duplication (three copies)
0(AAA), 1/3(AAB),
2/3(ABB), 1(BBB)
log2 (3/2) ≈ 0.58

copy-neutral LOH
0(AA), 1(BB)
log2 (2/2) = 0

Table 1.1: Theoretical values of BAF and LRR at different AI regions
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1.2

Motivation
CNVs take a sizable portion in human genomes. A study of the CNVs in

270 individuals from four populations with ancestry in Europe, Africa, or Asia
(from human HapMap project) discovered that 12% of the human genome (360
megabases) is copy number variable [11]. It has been known that CNVs associate
with many diseases such as mental illness, developmental disorders, and cancer
[12, 13, 14, 15, 16, 17, 18], and it is an underlying component of evolution [10].

1.2.1

CNVs and congenital disorders
Recurrent CNVs, resulting from the predisposing genomic architecture, have

been found associated with many congenital diseases. Unlike Mendelian diseases
that can be detected through linkage analysis, there is no inheritance pattern to follow in diseases caused by de novo CNVs. There are many challenges ahead for the
study of the potential de novo mutation-related genomic disorders, such as finding
the causative mutations and laying out the timeline (whether it arose during gametogenesis or postzygotically). Yet the mechanism and associated stochasticity
of the genesis of CNVs have not been well studied, particularly at the population
level.
There has been greater attention on de novo deletions related to many congenital anomalies but less focus on de novo duplications because it is considered
that deletions are more likely to result in deleterious consequences than the redundancy created by the extra copies of DNA in duplications [19, 20]. The fact
is, that the de novo deletions arose by NAHR have always been accompanied by
the de novo duplications of the same genomic region. If the affected region encompassed the dosage-sensitive gene, both deletions and duplications would be
6

pathogenic. Examples include William-Beuren syndrome caused by the deletion
of 7q11.23 and the 7q11.23 duplication syndrome, as well as Charcot-Marie-Tooth
(CMT) type 1A (CMT1A) caused by the duplication of 17p12 [12] and hereditary
neuropathy with liability to pressure palsy (HNPP) caused by the deletion of the
same region. Therefore, studying and charaterizing de novo duplication in more
details is also important.

1.2.2

CNVs and cancers
Genome instability and mutation is one of the two enabling characteris-

tics of cancer hallmarks [21]. It drives the tumor progression through the acquisitions of single nucleotide alterations and chromosomal rearrangements. Acquired
CNVs (somatic copy number alterations) are very common in cancerous genomes,
either being the driver mutations or the passenger mutations [22, 16]. CNVs can be
triggered by the exposure of the exogenous carcinogens such as Nicotine-derived
nitrosamine ketone (NNK) [23], Ultraviolet (UV) rays [24], and ionizing radiations.
CNV can also be triggered by the cellular carcinogens such as other driver mutations, protein dysfunctions, etc. Moreover, germline CNVs may also predispose
some types of cancer [25].
Tumor heterogeneity is the result of tumor evolution and presents the dynamic feature of the cancer genome. Different cancer cells can have distinct morphological and mutational profiles, and the heterogeneity can be observed either
between tumors (inter-tumor heterogeneity) or within tumors (intra-tumor heterogeneity). It is often seen that within the same bulk tumor, there are more than two
subclonal populations of cells exhibiting different molecular features. The tumor
heterogeneity raises significant challenges in study of specific cancer cell signatures and the design of effective treatment. A common way to quantify the tumor
7

heterogeneity is through comparison of the CNV profiles from intra-tumor multiregion sequencing [26]. Furthermore, the haplotype composition of the CNVs will
provide more details into the evaluation of the shared / distinct CNV profiles.

1.2.3

Evolutionary significance
Like many other initiative investigations in biology, yeasts has been used as

a model to investigate the impact of structural variation on evolution. By mapping
two different Saccharomyces cerevisiae genomes together with a Kluyveromyces
waltii genome [27], Kellis et, al. proved that the variation between S. cerevisiae
genomes was caused by whole-genome duplication following by multiple genes
losses. As the most complex genome, human genome is shaped by all the types
of mutations. And it is fair to say that all of the genetic variations was once a de
novo germline mutation in an individual in evolution [28, 29]. Even the SDs, the
underlying factors for NAHR, were once created by de novo CNVs and now are
constructing the complex structure of human genomes.

1.2.4

Differentiation of inherited and acquired CNVs
A de novo duplication can provide more information about NAHR than a

de novo deletion. If a rearrangement product was transmitted to the offspring, it
is hard to differentiate it from a somatic mosaic event, especially from one that
occurred during early development. Unless, the additional information within a
de novo duplication can further validate the genesis time and origin, i.e., carrying
a third haplotype that wasn’t belong to any of the two transmitted chromosomes.
For example, in the previous studies, size is one of the measurements used to differentiate somatic mosaic events from germline de novo CNVs because the latter
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should be comparatively shorter. But it is hard to draw a threshold to categorize
the two. Here, we aim to disentangle the de novo duplication configuration to better
understand the NAHR mechanism. In parallel, a monozygotic (MZ) twin model
can help us to tell the type of an event: events existing in both MZ twins should be
germline transmitted de novo; while a event existing in only one MZ twin should
be somatic mosaic.
From the presentation of the genotype information (BAFs and LRRs), it is
difficult (often impossible) to determine exactly when does a de novo CNV arise.
A CNV occurred in parental meiosis (germline de novo) versus a CNV occurred in
early cycle after the zygote formation (germline mosaicism) will both present in
nearly 100% of the cells. Even when compare to a somatic mosaic CNV, with the
unavoidable perturbation from random noise, it is hard to differentiate it from a
germline event when the somatic mosaic event is in a large fraction of the cells being genotyped. With additional measurements such as BAF deviation and LRR deviation [30], it is applicable to draw thresholds to characterize the CNVs. However,
for the events ambiguously close to the threshold, it is hard to truly distinguish an
inherited versus a mosaic event. To partially target this challenge, utilizing the
additional information of the haplotypes in a copy number duplication seems to
be plausible to determine whether a duplication result from inter-chromosomal
NAHR thus confirm whether the event is germline de novo. De novo duplication
can provide a picture with better resolution of the origin and formation of the genesis mechanism.

9

1.3

Computational methods for CNVs detection
Circular binary segmentation (CBS) algorithm [31] was designed for calling

CNVs from array comparative genomic hybridization (arrayCGH) data and then
being applied to SNP array analysis. It detects the segments of consistent copy
numbers through testing for the change-points in the LRRs. QuantiSNP [32] and
PennCNV [33] are the two hidden Markov model (HMM)-based methods that interrogate both LRRs and BAFs to detect the copy number changes and infer the
copy number states. In addition, PennCNV has a module specifically for calling
CNVs from trio data [34].

1.4

The overview of dissertation
This dissertation consists of two projects, focusing on development and de-

ployment of computational tools for the studies of inherited and acquired CNVs by
utilizing the observed or estimated parental haplotype information to resolve the
complicated configurations of CNV structure. It is organized as follows. Chapter
2 describes the development of a novel algorithm of incorporating parental haplotypes to explore and quantify the processes in the genesis of the DNA copy number
duplication at meiosis as well as its applications to three large trio datasets generated by several Illumina genome-wide SNP array platforms. Chapter 3 describes
the deployment of existing and emerging tools for the study of acquired mutations
in macro-dissected carcinomatous, sarcomatous, and normal tissues from uterine
carcinosarcoma (UCS) patients. Chapter 4 discusses the significance of this dissertation may bring to the scientific field, the limitations and the potential improvements of our studies, and the future directions we can pursue.

10

Chapter 2
Inferring the duplication configurations of de novo duplications

2.1

Introduction
Copy number variation (CNV) is defined as chromosomal copy number

gains or losses of a stretch of DNA among individuals in a population. De novo
refers to a CNV in the offspring that is not present in the parents. Non-allelic
homologous recombination (NAHR) during meiosis is generally considered the
major mechanism for the genesis of de novo CNVs, with the breakpoints aligned
in the defined regions of highly identical sequences called segmental duplications
(SDs; Figure 2.1). The process results in two reciprocal products: a deletion of the
affected genomic region in one chromosome and a duplication of the same region
in the other chromosome. De novo CNVs have been associated with pathogenic
abnormalities such as intellectual disability, developmental delay, and neuropsychiatric disorders [12, 13, 14, 15, 17]. Unlike Mendelian diseases that can be detected through linkage analysis, there is no inheritance pattern to follow in diseases caused by de novo CNVs. For example, an affected child may carry a CNV
which appears to be pathogenic and inherited (present in the parental germ cells)
but does not have a family history of the disorder. There are many challenges
to the study of such congenital disorders, such as finding the causative mutations
and the origin. The mechanism and associated stochasticity of the genesis of CNVs
have not been well studied, particularly at the population level.
Turner et al. [35] developed a sperm-based assay to measure the germline
rates of de novo CNVs resulting from NAHR in males. Their method has been
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used in many subsequent studies but with two limitations. First, it requires finemapping meiosis NAHR hotspots to conduct such experiments, which may restrict
the investigations to only the hotspots related to common pathogenic rearrangements. Second, it can only study the mechanism in sperm cells, which may bias
the estimation of the actual presentations of de novo CNVs at the population level
[35, 36]. The alternative approach is to computationally scan the whole genome
and deconvolve the haplotype structures in the CNV regions. Palta et al. have
developed a method called PiCNV to phase the CNV regions in nuclear families [37]. It can study the composition and inheritance of haplotypes within the
pre-determined CNV regions, based on the genotypes at each locus of parentsoffspring trios. Their method is primarily designed for inherited CNVs where the
CNVs are also present in one of the parents, but fails to resolve the structure of the
de novo duplication.
We aim to study NAHR through the analysis of de novo duplications, which
have not been extensively characterized. There are two possible sources for the extra copy of DNA in a de novo duplication region during meiosis: (1) the transmitted
chromosome itself (probably arising from inter-chromatid NAHR [35]), or (2) the
homolog of the transmitted chromosome (probably arising from inter-chromosomal
NAHR [35]). Figure 2.1 shows analog examples of the two types of NAHR. The colored blocks represent haplotypes in which the numbers indicate the corresponding genomic locations. The colors blue and red indicate homologous chromosomes. The same color (e.g. the blue in Figure 2.1a) indicates sister chromatids
during DNA replication. The green regions are SDs, which are potentially NAHR
hotspots. For convenience, we name the duplication resulting from inter-chromatid
NAHR a “bi-allelic” duplication because there are at most two distinct haplotypes
within the region (Figure 2.2). We refer to the duplication resulting from inter12

(a)

(b)

Figure 2.1: Non-allelic homologous recombination (NAHR) mechanism
overview. The green bars indicate the locations of tandem repeats. The numbered blocks are haplotype blocks in the genome. And the blue and the red colors
indicate paternal and maternal chromosomes. (a), an example of inter-chromatid
NAHR which results in a duplication of identical haplotype block 2 in one chromosome and a reciprocal deletion in another chromosome. (b), an example of interchromosomal NAHR which results in a duplication of the homologs haplotype
block 2 in one chromosome and a reciprocal deletion in another chromosome.
chromosomal NAHR as a “tri-allelic” duplication because there are three distinct
haplotypes (Figure 2.2).
Here we propose a statistical model to gain insights into the genesis of de
novo duplication from population level genotype data (SNP array). Our goal is to
infer the duplication configurations (tri-allelic, bi-allelic, and complex) as well as
the parent of origin of the duplications. By analyzing three population datasets
with family trio or quad structures, we are able to estimate the rates of different
types of de novo duplication configuration. We further show evidence to support
the genesis theory of tri-allelic and bi-allelic in meiosis NAHR from our monozygotic twins (MZ) data. In addition, we find three potential NAHR hotspots where
several recurrent tri-allelic events clustered.
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Figure 2.2: An illustration example of the duplication transmission in a parentsoffspring trio. The homologous chromosomes are presented by different colors in
each individuals. Assuming no crossover events, the offspring “normally” inherited the purple chromosome from maternal and the blue chromosome from paternal. For a maternal transmitted duplication, we named it: (a) bi-allelic (the purple
segment) because it has two distinct haplotypes for a duplication; or (b) tri-allelic
(the orange segment) because it has three distinct haplotypes.
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2.2

Methods
For the purposes of our study, we define a de novo duplication to be a chro-

mosomal copy number gain present in the diploid germ cells and blood of an offspring (total copy number 3) that did not exist in either parent’s constitutional
DNA. This would result from a mutation in the formation of a parental germ cell
(egg or sperm) during meiosis and its genesis mechanism may due to non-allelic
homologous recombination (NAHR)

2.2.1

Notation and model

Figure 2.3: Example of a de novo copy number duplication. From top to bottom are father, mother, offspring. The first column plots the BAF values along the
genomic coordinates and the second column displays the histogram of the BAF
values within the duplication region (blue area). The third and the fourth columns
are the LRR values showing the same pattern as the BAF plots. Blue represents
BAF data and orange represents LRR data within the duplication region. Gray in
the first and the third columns represents the corresponding data for the normal
neighboring region of the duplication.
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We start with observed offspring “B allele” frequencies (BAFs) b and parental
haplotypes ĥ, which we assume are known, where ĥ comprises the complete set
of 4 (parental) haplotypes in the duplication region. In practice, we estimate ĥ
and consider a strategy to accommodate errors in these estimates later. Let our
phenomenon of interest, the occurrence of a tri-allelic versus bi-allelic de novo duplication, be represented by u as follows:

u=




0,

bi-allelic de novo duplication



1,

tri-allelic de novo duplication

.

Inference of u, given b and ĥ, can be obtained as follows, assuming the
configurations are equally likely a priori:

p(u = 1|b, ĥ) =

p(b|u = 1, ĥ)
p(b|u = 1, ĥ) + p(b|u = 0, ĥ)

.

(2.1)

To model the genesis and transmission of the duplication, we consider parental
chromosomes as the source material (meiosis) and assume no translocation. We
integrate over all 16 combinations of the transmitted haplotypes and source haplotype for the duplication; half of these, naively, would generate a bi-allelic (or
tri-allelic) duplication. In the following equation, i = {1, 2} index maternal transmission and j = {1, 2} index paternal transmission. And the parental source of
the duplication f = {0, 1} index the origin of the duplicated DNA as from mother
or from father, respectively. The conditional likelihood can then be obtained as
follows:
p(b|u, ĥ) =

X X X

p(b|u, ĥ, i, j, f ) × p(i, j, f ),

(2.2)

i=1,2 j=1,2 f =0,1

where we assume p(i, j, f ) is a constant. Since the haplotype configuration cap16

tures the dependence among markers, {u, ĥ, i, j, f } together define the haplotype
composition and thus the genotype of each marker (gn ). We defined the informative markers as the markers where they are heterozygous in at least one parent.
The probability density of the observed BAF data in the sequence of duplicated alleles given all the parameters defining the haplotype composition can be obtained
as:
N
Y

p(b|u, ĥ, i, j, f ) =

p(bn |u, ĥ, i, j, f ),

(2.3)

n=1

where N is the number of informative markers within the duplication region.
The likelihood function on the right-hand side of Equation (2.3) can be calculated from a combined parametric model. Within a duplication, there are four
possible genotypes for each marker, i.e.

{AAA, AAB, ABB, BBB},

where “A” is the arbitrarily chosen reference allele and “B” is the alternative allele. The canonical values for the BAFs corresponding to each genotype will be
{0, 13 , 23 , 1}. To account for the noise in observed BAFs depicted by the second
column in Figure (2.3), we assume a distribution for bn around the intermediate
canonical values and discretize the probabilities at the boundaries as follows:




f (bn ; δ, q1 )







f (bn ; u1 , σ 2 )


2


f (bn ; u2 , σ )





f (bn ; δ, q2 )

= δ I(bn <q1 ) (1 − δ)I(bn ≥q1 ) , if gn = AAA
∼ N (u1 , σ 2 ), if gn = AAB
2

∼ N (u2 , σ ), if gn = ABB
= δ I(bn >q2 ) (1 − δ)I(bn ≤q2 ) , if gn = BBB

17

.

(2.4)

We set δ = 0.95, u1 = 31 , and u2 = 23 . And we estimate q1 , q2 and σ empirically based
on the BAF values from the loci in the normal region of each sample.
We can also substitute u by f in the model above to make inference on the
parent (gender) from which the duplication arose (Appendix A.1.2). Or we can
calculate the joint probability of u and f , which offers information about the duplication configuration and the parental source together (Appendix A.1.3).

2.2.2

Segmentation inference
Intuitively, the sensitivity of our model should increase with the number

of informative markers. Incorporating the linkage disequilibrium (LD) information, i.e., the dependency among proximal alleles has the potential to improve our
model’s performance, compared to using a voting scheme to select the most plausible duplication configuration by treating each allele independently. However, for
a large duplication region, our model’s performance is more likely affected by the
phasing errors in the estimated parental haplotypes. To illustrate, let us assume
that there is an error in one of the estimated parental transmitted haplotypes in the
region where the offspring has a de novo duplication. A less-disruptive scenario is
when an error occurred in one of the two ends of the duplication. Our inference of
u is less perturbed because the estimated haplotype structure is mostly intact. A
more disruptive scenario is when an error occurs in the middle of the duplication,
as then the data and the haplotype configurations will not be sufficiently consistent to indicate the phenomenon, putting pu1 less informative and probably close
to 0.5. We sought to address this by considering the problem in a series of consecutive “chunks” of markers (e.g. at least 20 informative markers). In this way,
only the segment having the switch error enclosed may be affected for estimating
u. The inferences for the rest of the segments should be consistent with each other
18

Figure 2.4: A figure to illustrate segmentation inference. Each red dot indicates
the pu1 for one segment. The segment index is ordered by the genome physical
location. Most segments here indicate the bi-allelic duplications.
and indicate a consensus “vote” for u.
In addition to examining the impact caused by switch error, this procedure
can also help to detect complex de novo duplications, a region containing both biallelic and tri-allelic. We will discuss it in next section.

2.2.3

Complex duplication
When we look at the results of the segmentation inference, we found that

several duplication events have the segmentation inferences forming a step-shape
pattern (e.g. see Figure 2.6). Within each, there are more than two consecutive
segments indicating the same configuration and the rest of the segments indicating the alternative. For instance, Figure 2.6(b) presents a de novo duplication in
8p23.3 (0.8 mb) from the autism dataset, where the first two segments (each with
50 informative markers) are inferred as bi-allelic (pu1 ≈ 0) and the other four segments are inferred as tri-allelic (pu1 ≈ 1). This is unlikely caused by a phasing error
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Figure 2.5: Possible mechanism generating complex duplications. Again, the
green and the purple bars are the locations of tandem repeats. The numbered
blocks are haplotype blocks in the genome. And the blue and the red colors indicate paternal and maternal chromosomes. The spontaneous or sequential nonallelic homologous recombination misalign the tandem repeats in non-allelic regions between the sister chromatid and homologous chromosomes, which results
in a duplication of identical haplotype block 2 and a duplication of the homolog
haplotype block 3. Here the corresponding reciprocal deletions were not shown.
for which may only alter one segment, not a consistent alteration of signals. As
a contrast, Supplemental Figure A.6 shows an example with consistent inferences
of bi-allelic but with a potential phasing error in the 3rd segment. We propose a
potential mechanism forming such complex duplication as in Figure 2.5. Further
description is given in Results.

2.2.4

Study samples and data
We obtained three datasets with parents-offspring relationships. For the

multiplex families (family with more than one child), we divided them into simplex trios. The first is from craniofacial study (dbGaP study accession: phs000095.v3.p1),
with 2078 trios from 6190 individual samples, genotyped on the Illumina Human610_Quadv1_B platform, yielding 569,479 SNPs after QC [38, 39]. The second
20

(a)

(b)

Figure 2.6: Examples of complex duplications revealed by segmentation evaluation method. Each red dot indicates the pu1 for one segment. The segment index
is ordered by the genome physical location. (a), A sample from craiofacial dataset.
(b), A sample from autism dataset. Both samples have consecutive segments indicating bi-allelic and tri-allelic duplications.
is from autism spectrum disorder (ASD) study (dbGaP study accession: phg000143.v1.p1),
with 1067 trios from 3195 individual samples, genotyped on the Illumina 1Msingle array platform, yielding 842,645 SNPs after QC [15]. The third dataset is
from Netherlands Twin Register study. It contains 486 families from 3708 samples. We discuss some of the results from this dataset separately in the following
sections as it is enriched by 260 monozygotic twin pairs and 2 identical triplets,
as well as 236 dizygotic twin pairs. We segregated the families into 1244 simplex
trios. The samples were processed on the Illumina GSA array platform. The total
number of SNPs being used in our analysis is 651,292.
All three studies have a mix of blood and non-blood (cell line or buccal)
samples. For various reasons we ignored results from cell lines mainly because
the potential of high frequency clonal mosaicism (detail discussion in Appendix
A.1.6). We focus on the trios with the offsprings drawn from blood samples due
to the comparable high DNA quality (Supplementary Figure A.4). Therefore, we
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reported our results from 1,670 trios in the craniofacial dataset and 748 trios in the
autism dataset. For the twin dataset, we did not exclude any samples based on the
DNA sources because we want to have as many samples in MZ twins as possible,
in which we will discuss the results separately.

2.2.5

Data preprocesses
We used PLINK (V1.07, 10/Aug/2009) to confirm relationships within fam-

ilies. Based on the PI_HAT value (expected IBD score), we remove any families
with unmatched parent-offspring relationship (false paternity or false maternity).
To estimate parental haplotypes, we phase the parents in each dataset separately without reference panels, treating all parents as unrelated. We used BEAGLE (version 4.1 (Jul 27, 2016)) [40] to phase the parents in the craniofacial (3,320
samples) and the autism datasets (1,494 samples) and used MACH (MACH 1.0)
[41] to phase the parents in the twin dataset (972 samples).
To identify regions of de novo duplications, we used PennCNV’s trio module with default options[33] and limited to those with only one extra copy (copy
number 3). In addition, we created our own filtering steps in an effort to reduce
“contamination” of results from clonal mosaicism (acquired duplications) by using the BAF deviation and the Log R Ratio (LRR) deviation. The BAF deviation
is the absolute deviation of the BAF values in the duplication region from the median BAF values of the normal diploid region across the genome for heterozygous
markers only. The LRR deviation is the deviation of the LRR values in the duplication region from the median LRR values of the normal diploid region across the
genome. We examined our data to exhibit sufficiently large BAF deviations (> 0.1)
and positive LRR deviations. The final step of confirming the de novo duplication
calls was the visual inspection of the BAF and the LRR data (similar to Figure (2.3)).
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2.3

Results
Calling de novo duplications

2.3.1

After the quality control steps, we found 56 de novo duplications from 1,670
trios (56/1670=3.4%) in the craniofacial study, and the size ranges from 55 kb to
59 mb, with the median of 428 kb. We found 16 de novo duplications from 748
trios (16/748=2.1%) in the autism study, and the size ranges from 52 kb to 832 kb
with the median of 152 kb. In the twin dataset, we found 23 de novo duplications
from 1244 trios (23/1244=1.8%), and the size ranges from 56 kb to 2 mb with the
median of 271 kb (Table 2.1 and Figure A.1). It is difficult and frankly impossible
to distinguish an early somatic mosaic event from a germline-transmitted de novo
event as they appear similar to each other in the presentation of genotyping data.
The set of de novo duplications we found will likely contain a few false positive
events.

2.3.2

Duplication configuration
For convenience, we denote p(u = 1|b, ĥ) as pu1 in what following that

pu1 ≈ 1 indicates a tri-allelic event and pu1 ≈ 0 indicates a bi-allelic event. Intermediate values of pu1 we consider as inconclusive for the purposes of categorical
summaries.
From our method for inference of duplication configuration, the result we
get is a probabilistic statement. Figure A.1 shows the distribution of pu=1 for
the three datasets. We categorized the configurations into four groups, bi-allelic
(pu=1 ≤ 0.1), tri-allelic (pu=1 ≥ 0.9), complex (composed of partial bi-allelic and
partial tri-allelic), and undeterminable (0.1 < pu=1 < 0.9). Table 2.1 lists the num-
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bers of events in each dataset based on our categorization above. We detected
22 bi-allelic, 23 tri-allelic and 3 complex de novo duplications in the craniofacial
dataset, with 8 de novo duplications undeterminable (mainly due to high homozygosity in the parent of origin in the duplication). In the autism dataset, we detected
7 bi-allelic, 4 tri-allelic and 1 complex de novo duplications, with 4 de novo duplications undeterminable. There are 9 bi-allelic, 5 tri-allelic and 2 complex de novo
duplications in the twin dataset, with 7 de novo duplications as undeterminable.
Data Sets

no. trios

Craniofacial
Autism
Combined C+A
Twins

1670
748
2418
1244

no. de novo
duplications
56 (3.4%)
16 (2.1%)
72
23 (1.8%)

no.
tri-allelic
23
4
27 (1.1%)
5

no.
bi-allelic
22
7
29 (1.2%)
9

no.
complex
3
1
4 (0.2%)
2

Table 2.1: Overall results of the three datasets.
Figure 2.7 shows the distribution of the inferred duplication configurations
from all three studies. The ratios between bi-allelic and tri-allelic are not statistically different. We therefore report the rates of duplication configurations from
the first two public datasets using the merged numbers. Overall, from 2418 trios,
we found 29 bi-allelic (29/2418=1.2%), 27 tri-allelic (27/2418=1.1%) and 4 complex
(4/2418=0.2%) de novo duplication events.
Figure 2.8 displays the size distribution of the duplications from the four
categories. The sizes of complex de novo duplications (green color in Figure 2.8) are
generally larger than the duplications in other categories mostly due to the mechanism; that is, to form such a duplication requires four similar tandem repeats
which is more likely to span a large section of a chromosome. A comparatively
smaller duplication is more likely to have a completely homozygous parental genomic region which will lead to an undeterminable duplication (grey color in Fig24

ure 2.8).

Figure 2.7: Percentage distribution of duplications configurations in all three
datasets. The blue color indicate the percentage of bi-allelic duplications. The red
is tri-allelic duplications, and the green is complex duplications. The gray color
indicates those duplications with undeterminable configurations.

Figure 2.8: The size distribution of four categories of duplications. The y-axis is
showing the size in kb and plotted in log scale.
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We separate the analysis of the twin dataset from the craniofacial and autism
datasets for the following reasons. First, most of the samples in the twin dataset
are from buccal swabs (98%), which does not offer the same DNA purity and thus
affect the precision in intermediate data sources such as the BAFs to our approach.
And the blood samples in the other two datasets have already provided us enough
information to estimate the duplication configuration rates, we do not want to bias
our estimation by a different DNA source. Second, PennCNV reported the initial number of de novo duplication events in the craniofacial dataset is 1,912 from
276 trios (16.5% of the offsprings), and in the autism dataset this number is 1,164
from 247 trios (33%). However, in the twin dataset, the initial number of de novo
duplications is 15,240 from 642 trios (51.6%). PennCNV apparently has low sensitivity in application to the twin dataset (maybe due to the array platform or DNA
source). In addition, among those de novo duplications passed visual inspection
(the last step in our QC), PennCNV only finds the event in one MZ twin but not
in its MZ twin sibship who also has the event, even in its pre-QC set of events. In
total, we have three such MZ twins which indicate that the CNV calling process
has low specificity in dealing with the twin dataset. Although our analysis in the
twin dataset is not conclusive, this dataset is helpful as serving the purpose of a
natural model of meiosis NAHR which is the potential mechanism creating de novo
duplications.

2.3.3

Analysis of monozygotic twin data
We detected six de novo duplications from individuals of MZ twin sibships.

In three of these six, we could confirm the existence of the duplication in the cotwin through inspection of the genotype data, though in none of these did we detect the duplication originally with PennCNV. These give some insights into false
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negatives by our approach in trios. The other three, not confirmed to show the
duplication in the co-twin, may be explained by mosaicism, which suggests false
positives. Overall, the events found in MZ twins provide some insights into the
plausibility that the de novo duplication arose from meiosis NAHR and allow for
the examination of the potential false positive de novo duplications. Intuitively, if
we see a tri-allelic event, it should be germline transmitted, otherwise, there won’t
be a third distinct haplotype. Figure 2.11 shows a de novo duplication event located
at 1p:36.13, which are observed in both MZ twins. The colored dots mark the event
regions (blue is BAF value and orange is LRR values). The grey dots are the neighboring alleles. The left two columns are data from father and mother and the right
two columns are data from the MZ twins pair. In this example, our model inferred
that pu1 = 0.99 for one twin (top) and pu1 = 1 for the other twin (bottom), supporting that they are both tri-allelic and thus inherited through germline. Another
example of de novo duplication event (5q:35.3) is shown in Figure 2.9, with pu1 = 0
for the events in both MZ twins, i.e. bi-allelic.
Figure 2.10 shows an example where one of the MZ twin have two de novo
duplications in 21q:21.2 (2 mb) and our algorithm inferred both of them as bi-allelic
duplications. However, we could not find the similar duplication pattern in its MZ
twin sibling. We considered this to be a somatic mosaic duplication formed in one
twin after the splitting of the zygote, for which inference of a bi-allelic configuration is expected. This highlights the possibility that some of the duplications we
inferred to be bi-allelic may, in fact, be acquired rather than inherited. A duplication that occurs in the first few cell cycles post-fertilization would be very similar
or identical for a single tissue to a de novo duplication.
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Figure 2.9: A family of MZ twins showing the bi-allelic events in both twins.
The first and the third columns are the B Allele Frequencies and the second and
the fourth columns are the Log R Ratios. The data are plotted from the father,
the mother, and two MZ twin siblings. The colored regions indicate where the
duplication event occur in the offspring. The blue is BAF value, and the yellow is
LRR value.
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Figure 2.10: A family of MZ twins showing the bi-allelic events only seen in one
twin, which indicate the events being somatic. The first and the third columns
are the B Allele Frequencies and the second and the fourth columns are the Log R
Ratios. The data are plotted from the father, the mother, and two MZ twin siblings.
The colored regions indicate where the duplication event occur in the offspring.
The blue is BAF value, and the yellow is LRR value.
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Figure 2.11: A family of MZ twins and a full sibling showing a potential
germline somatic duplication. The duplication is not seen in both parents. And
our method indicates that the events in all three children are all tri-allelic. The first
and the third columns are the B Allele Frequencies and the second and the fourth
columns are the Log R Ratios. The data are plotted from the father, the mother, and
two MZ twin siblings. The colored regions indicate where the duplication event
occur in the offspring. The blue is BAF value, and the yellow is LRR value.
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MZ Twins 1:
MZ Twins 2:
MZ Twins 3:
MZ Twins 4:
MZ Twins 5:
MZ Twins 6:

event_type for twin 1
tri-allelic
(pu1 = 0.99)
bi-allelic
(pu1 = 0)
undeterminable
(pu1 = 0.75)
bi-allelic
(pu1 = 0)
complex
(pu1 = 0.97)
undeterminable
(pu1 = 0.65)

po

event_type for twin 2
tri-allelic
(pu1 = 1)
bi-allelic
(pu1 = 0)
undeterminable
(pu1 = 0.75)

po

region

m

1p:36.13

f

5q:35.3

u

14q:11.2

m

no-event

-

21q:21.2

m

no-event

-

8p:23.1

u

no-event

-

11q:13.2

m
f
u

Table 2.2: The details of duplications found in MZ twins.

2.3.4

Complex duplications
We define a complex de novo duplication as consisting of both bi-allelic and

tri-allelic configurations. In a complex event, the markers can be divided into consecutive sections where each section has a different duplication configuration type.
This can be detected by our segment posterior inference (2.2.2) if a pattern similar
to one of the two figures in Figure (2.6) is observed. Overall, we found three complex de novo duplications in the craniofacial dataset, one in the autism dataset, and
two in the twin dataset (see Figure 2.6 and Table 2.3). The locations, the approximate beginning, ending, and the breakpoints are listed in Table 2.3.
A possible mechanism of complex de novo duplication is shown in Figure 2.5. We seek for evidence to support this hypothesized mechanism in silico
through another aspect in our model, by inferring the parent of origin in each segment of duplications. The logic here is that a true complex de novo duplication
should have transmitted both tri-allelic and bi-allelic duplications from the same
parent. In other words, if the complex duplications we found were just introduced
by random noise, we would expect to see half of them originated from different
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parents for the bi-allelic and the tri-allelic regions. We inferred the parent of origin separately for the putative bi- and tri-allelic regions and found that for five of
six complex events, both regions clearly came from the same parent with the sixth
being inconclusive due to a short segment length for one of the regions (see Table
2.3).
Events Locations

dataSet

4p:16.1

Craniofacial

12q:13.12-13

Craniofacial

11p:15.2-11p:13

Craniofacial

8p:23.3

Autism

3p:12.3

Twins

8p:23.1

Twins

start
7789269
7902977
51185507
51552473
13869322
23789099
712942
1019625
75358613
75458314
6926296
6995876

end
7892733
8190858
51548138
52757547
23788002
35344450
1016907
1521910
75453294
75831763
6986156
8098038

configuration
bi-allelic
tri-allelic
tri-allelic
bi-allelic
tri-allelic
bi-allelic
bi-allelic
tri-allelic
bi-allelic
tri-allelic
bi-allelic
tri-allelic

parental origin
father
father
father
father
mother
mother
father
father
mother
mother
undefine
mother

Table 2.3: The information about the complex de novo duplication

2.3.5

Parents of origin
When applying our model to infer the parent of origin for the extra copy

of DNA in a de novo duplication, the same cutoff (0.1 and 0.9) for pf 1 was applied
to determine whether the genotype data support one of the parents of origin. If
0.1 < pf 1 < 0.9, the duplication region will be marked as inconclusive in terms
of its source of parents. We found 23 paternal transmitted and 30 maternal transmitted de novo duplications in the craniofacial data. This is within the expectation
because in general, the recombination rate in a female is higher than in a male
(1.3-fold) [42]. We found 9 paternal transmitted and 4 maternal transmitted de
novo duplications in the autism data. There are more than two-fold enrichment
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towards paternally transmitted duplications which is corresponding to what has
been previously reported [43, 44], assuming the detected events are contributing
to the autism phenotype. We were not able to determine the parental sources of 3
duplications from each dataset because they are small events (Figure 2.12 b) and
thus the haplotypes between parents are similar. We also found 8 paternal transmitted and 9 maternal transmitted de novo duplications in the twin data, along
with 6 events of unclear parental origins. Figure (2.12) presents the numbers of
paternal and maternal transmitted de novo duplications in the two datasets as well
as their size distribution. The same color scheme is applied throughout (blue is
bi-allelic, red is tri-allelic, green is complex and gray is undeterminable). There are
two complex de novo duplications from paternal transmission and one complex de
novo duplication from maternal transmission in the craniofacial data. The complex
de novo duplication in the autism dataset is from paternal transmission.

2.3.6

Recurrent duplications in specific genomic locations
We looked at the genomic regions of the de novo duplications in the three

datasets and generated a genome-wide plot for the approximate genomic locations
of all the events (Figure 2.13). We investigated if there were specific de novo duplication hotspots or spatial coincidences of mutation types. There are three genomic
regions, 7q11.23, 22q11.21 and 22q11.23, showing more than three de novo duplication clusters. We found three craniofacial samples with tri-allelic duplications in
chromosome 7:q11.23 (Table 2.4), a region well known as William’s Syndrome critical region for deletion [45]. Duplications in this locus have also been reported to
be associated with developmental delay and other abnormalities for duplication
[46]. We found four craniofacial samples with tri-allelic duplications in chromosome 22:q11.21 (Table 2.5). And two craniofacial samples (blood) plus one autism
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Figure 2.12: The distribution of the parental origins of the de novo duplications.
(a) The counts of maternal, paternal and undeterminable transmitted duplications
as well as the corresponding counts of different duplication configurations. (b)
The size distribution of the maternal, paternal and undeterminable transmitted
duplications.
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sample (cell line) with de novo duplications in chromosome 22:q11.23 (Table 2.6),
of which two are tri-allelic and one is undeterminable. The undeterminable duplication in the craniofacial sample is due to homozygosity in the maternal genomic
region. These two regions on chromosome 22 (22q11.21 and 22q11.23) have also
been reported to be associated with the craniofacial phenotype [47]. To make sure
these clustering events are not artifacts from the sample contamination or the sample swap, we used PLINK to examine the relationships between and within trios.
We confirmed that all the offsprings are independent samples and hold true for the
parents-offspring relationships in the two datasets.
dataset
Craniofacial
Craniofacial
Craniofacial

startSNP
(startPos)
rs11544045
(72355845)
rs11544045
(72355845)
rs11544045
(72355845)

endSNP
(endPos)
rs10233478
(73620443)
rs1637414
(73782113)
rs6956055
(73617066)

length
(kb)
1265

duplication
types
tri-allelic

DNA source

1426

tri-allelic

blood

1261

tri-allelic

blood

blood

Table 2.4: The clustering of events in chromosome 7: q11.23

dataset
Craniofacial
Craniofacial
Craniofacial
Craniofacial

startSNP
(startPos)
rs2543958
(17257787)
rs2543958
(17257787)
rs2543958
(17257787)
rs9604821
(15392935)

endSNP
(endPos)
rs140392
(19792353)
rs140392
(19792353)
rs854961
(18658004)
rs1210829
(18688800)

length
(kb)
2534

duplication
types
tri-allelic

DNA source

2534

tri-allelic

blood

1400

tri-allelic

blood

3296

tri-allelic

blood

Table 2.5: The clustering events in chromosome 22: q11.21

34

blood

dataset
Autism
Craniofacial
Craniofacial

startSNP
(startPos)
rs9612921
(23991725)
rs138558
(23994408)
rs138558
(23994408)

endSNP
(endPos)
rs79091
(24240667)
rs7288183
(24244593)
rs7288183
(24244593)

length
(kb)
249

duplication DNA source
types
tri-allelic
cell line

250

tri-allelic

250

undeterminable blood

blood

Table 2.6: The clustering events in chromosome 22: q11.23

2.4

Duplication configuration inference without the trio structures
Our model uses the parental haplotype information to infer the de novo du-

plication configurations. It is rather robust but requires the trio structure which is
not commonly collected in general settings. Therefore, we seek to make inferences
about duplication configurations in unrelated individuals by using measurements
of the duplications themselves. Heterozygous density represents the proportion
of heterozygous markers in a region. A duplication is expected to have a higher
rate of heterozygous markers if it is a tri-allelic versus being a bi-allelic. It can
be observed from Figure 2.14 where both the craniofacial and the autism datasets
show that the distribution of tri-allelic duplications (red) is higher than bi-allelic
duplications (blue) (Student’s one-sided t-test p = 0.004). Phase concordance is a
measure to access the local switch consistency of the phased diploid haplotypes
by comparing to the BAF-excessive haplotype [48]. In a normal diploid region, the
phase concordance is around 0.5 because of the randomness of the BAF-excessive
haplotype. A tri-allelic duplication also has a low phase concordance due to the
randomness in failing to resolve the correct phased forms of the haplotypes. In
contrast, the phase concordance of a bi-allelic duplication may be higher or even
close to 1, because the duplicated chunk of DNA have pushed the excessive haplotype to the same direction for almost all the markers in the region. The differences
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in the phase concordance scores between bi-allelic and tri-allelic duplications can
be seen in Figure 2.15 (Student’s one-sided t-test p = 2 × 10−12 ). However, heterozygous density or phase concordance solely are not able to draw dichotomized
thresholds to differentiate between a bi-allelic and a tri-allelic duplication. Instead
combining the phase concordance and the heterozygous density together provides
a good classification strategy between the two configuration groups (see Figure
2.16). We incorporate these two variables into a simple weighted logistic regression model to predict the duplication configuration. Here, we use our existed data
to illustrate the process. Combining the craniofacial and autism datasets (72 de
novo duplications) and excluding the 12 undeterminable events, we assume that
we have 60 events with known duplication configurations. And for those four
complex duplications, we separate each into two independent events. Therefore
in total the sample size is 64 and the duplication configurations is a binary variable (bi-allelic or tri-allelic). The weighted logistic regression model will take into
account the precision of the calculation for heterozygous density and phase concordance. Here, if the predicted value Ŷ is within 10% deviation from the actual
observed value Y , i. e. , we denoted this as a fitted value. We take the leave-oneout approach to evaluate our model’s performance and the prediction accuracy is
82%.

2.5

Discussion
Germline transmitted de novo duplications play an important role in the

studies of genomic disorders, meiosis mechanisms, and evolution. However, there
has not been a comprehensive characterization of the relative frequency of the different genetic configurations; observing de novo duplications offers a chance to do
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this. In this work, we have developed a haplotype-aware statistical model to differentiate between configurations of de novo duplications, which are the tri-allelic
duplications (arose from inter-chromosomal NAHR) and the bi-allelic duplications
(arose from inter-chromatid NAHR).
In order to trace the transmission of the haplotypes in the genesis of a duplication from parent to their offspring, ideally, we would explicitly evaluate the
haplotypes in the offspring and identify the “extra” piece of chromosome. However, conventional genotyping technologies like SNP arrays and next-generation
sequencing do not allow direct inference of haplotype structures. Although phasing algorithms exist for polyploid organisms [49], we did not attempt to use them
here, as they would require further assumptions. Instead, our statistical method
deals with imprecision in genotyping and infers the configuration of the de novo
duplication by utilizing estimated parental haplotypes and observed B allele frequencies in the offspring.
By examining 2,418 trios from two family-based population datasets (1,670
craniofacial, 748 autism), we estimated the rate of tri-allelic duplication as 1.1% and
the rate of bi-allelic duplication as 1.2%. During meiosis I, the frequency of interchromosomal NAHR is expected to be 2-fold of inter-chromatid NAHR. The next
step in meiosis II should result in additional inter-chromatid NAHR only, which
will increase the expected number of bi-allelic duplications and may explain the
balanced ratio between the two configurations seen in the offsprings. We should
note that our model’s sensitivity is associated with the number of heterozygous
markers in the event. Thus the rate of bi-allelic and tri-allelic would be higher than
what we estimated above since there are a few de novo duplications with inconclusive inferences (0.1 < pu1 < 0.9) due to the limited size of the region (undeterminable events).
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Our estimated rates of de novo duplications (1.8% - 3.4%) are higher than
what has been reported previously (1.4% - 1.6%) [50]. In the craniofacial dataset,
the rate of de novo duplication is almost twice that reported in any of the datasets.
This may not be surprising. Itsara et al. stated that their estimations were rather
conservative. In addition, this higher rate could be due to phenotypic ascertainment, since autism and craniofacial disorder are two phenotypes known to be associated with de novo CNVs. Although we assume our analyzed duplications are
true and de novo, in practice we cannot rule out potential “contaminations” by somatic mosaic events, which has probably slightly biased upwards our estimated
ratio of bi-allelic to tri-allelic events.
Meanwhile, our analysis of the monozygotic twin pair data helps further
validate our findings as well as provides a way to evaluate the false positives and
the false negatives of the input de novo duplications in our model. The same duplication configurations found in both MZ twins are possibly the results of meiosis
NAHR while the duplication found in only one individual in the MZ twin pair is
likely a somatic mosaic event. Additionally, the de novo duplications that the CNV
detection algorithm failed to detect are the supporting evidence of the false negatives in our analyzed de novo duplications. Neither the false positives nor the false
negatives are avoidable because it is difficult to distinguish mosaic events from
germline de novo events (Figure A.8) and no CNV calling software can generate an
exhaustive list for a sample [51].
We discussed and reported the rate of complex de novo duplication, a duplication likely arising from spontaneous inter-chromatid and inter-chromosomal
NAHR. We estimated the rate of the complex events among de novo duplications as
6% (4 out of 72). It is quite intriguing to consider that every NAHR may have a 6%
chance of being generated by two sets of SDs, which reflects the complexity and
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instability of our genome. Further molecular examination may be useful to characterize these events; however, our haplotype-based analysis quite convincingly
documents their existence.
Furthermore, our method may help provide insights into the mechanism of
pathogenic de novo duplications. Many CNV detection algorithms can detect these
regions for duplication but cannot infer the detailed structure of the haplotype
composition within. A tri-allelic duplication could help us roughly triangulate
the timing of the duplication formation to meiosis since it carries the extra piece
of DNA from the non-transmitted homologous chromosome which can only arise
during meiosis while the homolog presents. In our analysis, we identified three
chromosomal regions that have events clustering together and sharing the same
duplication types, mostly tri-allelic (section: 2.3.6). Those regions overlapping or
close to the known SD locations provide further evidence that the genesis mechanism is NAHR. Meanwhile, presentation as a tri-allelic supports the duplication
as a germline-transmitted de novo and partially explains the observed recurrence.
We interrogated the germline of these individuals in a novel way, discovering that
they carry three distinct alleles within the critical region, generating potential hypotheses of pathogenic events and, importantly, putative mechanisms for further
study.
The current low cost of the SNP array and sequencing technologies will facilitate the generation of increasingly large sets of family-based genotype data from
the general population. From these, more extensive examinations using methods
such as ours will enable identifications of the critical events associated with various phenotypes, and we will be able to more accurately and more efficiently estimate the rates of tri-allelic, bi-allelic, and complex de novo duplications in normal,
putatively healthy populations.
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Figure 2.13: The genome wide map of all the de novo duplications as well as their configurations from the three
datasets. The blocks under the chromosomes represent one event. The size of each block is not necessarily proportional to its actual length. If there are recurrent/overlapping events in different individuals, the blocks will be stacked
up under each chromosome.

Figure 2.14: Heterozygous density distribution for different duplication configurations.

Figure 2.15: Phase concordance distribution for different duplication configurations.
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Figure 2.16: The combination of phase concordance and heterozygous density
distinguish the duplication configurations.
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Figure 2.17: The prediction error for each samples with the leave-one-out approach. The colors indicate the observed configuration types and the shapes indicate the data source.
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Chapter 3
Assessing inter-component heterogeneity of biphasic uterine
carcinosarcomas

3.1

Abstract:
Motivation: Uterine carcinosarcoma (UCS) is a rare and aggressive form of

uterine cancer. It is bi-phasic, exhibiting histological features of both malignant
epithelial (carcinoma) and mesenchymal (sarcoma) elements, reflected in ambiguity in accepted treatment guidelines. We sought to study the genomic and transcriptomic profiles of these elements individually to gain further insights into the
development of these tumors.
Method: We macro-dissected carcinomatous, sarcomatous, and normal tissue from formalin fixed paraffin embedded (FFPE) uterine samples of 10 UCS patients. Single nucleotide polymorphism (SNP) microarrays and deep sequencing
( 6000x) of 26 cancer genes were performed on samples from nine of the patients.
RNA-sequencing was performed for transcriptome profiling on samples from all
10 patients. Somatic chromosomal alterations (SCAs), point mutation and gene
expression profiles were compared between carcinomatous and sarcomatous components.
Results: Mutations in TP53 and MSH6 were prevalent, detected in 67% and
61% of samples respectively. Other recurrently mutated genes identified include
FBXW7, FGFR2, KRAS, PIK3CA, CTNNB1 and PTEN, all of which have been previously identified in gynecologic carcinosarcomas. Mutations identified in carcinomas were identical to those in their sarcoma counterparts in 90% (38 of 42) of
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the total mutations identified. Chromosomal alteration profiles were also highly
similar with a mean of 89% genomic sharing of SCAs between paired carcinoma
and sarcoma samples. Differential expression analyses between components failed
to identify any component-specific aberrant cancer pathways. However, clustering of samples based on known epithelial-mesenchymal transition (EMT) genes
showed that EMT-like (versus epithelial-like) statuses were more common in the
sarcomas (5 of 8) versus carcinomas (2 of 6). EMT-like status was more common in
advanced stage patients (p = 0.02) and was associated with higher degrees of intercomponent heterogeneity based on degree of SCA dissimilarity (p = 0.03). Further,
for all 3 of the UCS tumors that exhibited inter-component mutation differences
with available EMT classifications, their sarcomas were classified as EMT-like.
Conclusion: Consistent with recent mutation-based studies, both carcinomatous and sarcomatous components exhibited similar molecular profiles, suggesting that components originated from a single clone. However, where intercomponent heterogeneity does exist, quantification of genomic differences may
provide insights into the progression of UCS and may be clinically informative.
Our results imply that higher degrees of mutational or SCA heterogeneity reflect
more advanced disease. In addition, gene expression classification of EMT-status
may provide similar insights into tumor progression. Of importance, we observed
that expression-established EMT status of the carcinomatous and sarcomatous components are often discrepant; therefore, in a mixed-cell population, profiling of the
UCS tumor in bulk may fail to resolve an EMT-like status, and thus a componentbased profiling approach may be required in this setting. In summary, our study
proposes that profiling of carcinomas and sarcomas separately and quantification
of inter-component heterogeneity may be clinically informative, possibly enabling
a refined staging of UCS, with more effective stratification of patients for current
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and future treatment modalities.

3.2

Introduction
Uterine carcinosarcoma (UCS), also referred to as Malignant mixed Mülle-

rian tumors of the uterus, is a malignant neoplasm of the female genital tract. As
implied, the neoplasm shows histological features of both epithelial elements (adenocarcinoma) and mesenchymal elements (sarcoma). Based on the mesenchymal
elements, UCS is categorized as either homologous or heterologous. Homologous
tumors contain sarcomatous elements native to uterine tissue (e.g., endometrial
stromal sarcoma, leiomyosarcoma, and undifferentiated endometrial sarcoma), whereas
heterologous tumors contain sarcomatous elements that are non-native to uterine tissue (e.g., rhabdomyosarcoma, chondrosarcoma, osteosarcoma, liposarcoma,
and fibrosarcoma). Patients with stage I homologous tumors have a greater 3-year
survival rate (93%), compared to that for patients with heterologous tumors (45%)
[52]. However, in more advanced, stage II-IV UCS diagnoses, there is no survival
difference between the two categories (REF). Overall, MMMT patients exhibit 5year survival of between 35% and 65% for early stage and 10% for late stages [53].
Although UCS is a relatively rare malignancy, representing less than 5%
of all uterine cancers, it is known for its aggressive clinical course and accounts
for a disproportionate number (15%) of all uterine cancer deaths [54]. This is due
to several factors, including late stage at presentation (10% of patients will have
metastatic disease and 60% will have extrauterine disease at time of diagnosis)
[55], and limited clinical trials investigating optimal treatment approaches. Therapeutic approaches developed uniquely for UCS are inadequate and borrowing
insights from other cancers has proved challenging. Indeed, UCS was tradition-
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ally classified as a sarcoma and treatments were thus directed as such. In 2009, the
International Federation of Gynecology and Obstetrics introduced a new staging
system for uterine sarcomas that made UCS a variant of endometrial carcinoma
[56], based on greater similarity in clinical course and risk factors, compared to
sarcoma. This recent change reflects a relatively shallow understanding of UCS,
motivating additional research toward understanding its pathology, progression
and tumor development, and how these relate to clinical outcome.
The unique biphasic nature of carcinosarcomas has given rise to a body
of work to better understand its origins. Three theories are generally accepted
as plausible [57, 58]. The collision theory indicates that the tumors are biclonal,
arising from separate cells that later merge. The conversion theory states that a
single cell undergoes metaplastic differentiation. Finally, the combination theory
captures aspects of the previous two, i.e. that a common precursor differentiates
bi-directionally before merging. Most molecular and histopathological evidence
is supportive of the conversion theory for a majority of tumors [58]. Wada et. al.
assessed the X inactivation patterns in 25 carcinosarcoma cases. They found similar patterns of X chromosome inactivation in 19 out of 25 cases, suggesting monoclonal (conversion or combination) derivation [59]. Other studies have shown
consistent patterns of deletions, preserved across carcinoma and sarcoma components, also suggesting monoclonal origin [60, 61, 62]. Schulten et al. showed 2
of 3 cases had similar karyotypic abnormalities with additional ones in the sarcomatous components. They also demonstrated the presence of frequent 8q gains
in both components of carcinosarcoma and de novo endometrial carcinoma, suggesting a monoclonal origin with additional genetic aberrations in areas having
undergone sarcomatous transformation [63]. While most clinical, histological, and
molecular evidence supports the conversion theory, and it is now generally as47

sumed that the neoplasm is derived from sarcomatous differentiation of highgrade carcinoma [64, 65], there are examples of a bona fide bi-clonal origin of the
tumor (collision theory) for some UCS patients. Wada, for example, found 3 patients exhibiting X-inactivation patterns indicating a collision origin [59]. From
these observations, it appears there exists heterogeneity in modes of UCS development, with a monoclonal origin as the more common mode. Further investigations
are required to better characterize their relative frequencies and understand their
clinical relevance.
McConechy et al, performed component-separated analyses, reporting DNA
mutations in 27 genes of 13 patients and reported mutation patterns that were consistent with a monoclonal theory [65]. Zhao et al performed component-separated
whole-exome sequencing analyses on 6 uterine and ovarian carcinosarcoma patients and indicated a similar conclusion [66]. The Cancer Genome Atlas for UCS
performed multi-platform molecular characterizations from unseparated, mixedcomponent cancer samples, studying both components of UCS via bulk analyses
[67]. While this comprehensive effort sheds light on the genomics and transcriptomics of this cancer relative to other sites, such a design is not geared toward
resolution of molecular origins and development of the disease.
Unavailable from deep DNA point mutations assessments of McConechy
et al [65] and Zhao et al [66], and the multiple-platform approach of TCGA is a
more complete picture of the landscape of somatic chromosomal alterations (SCAs)
leading to acquired allelic imbalance in each tissue component, as well as a corresponding analysis of gene expression profiles. Here we sought to address this void,
obtaining separated carcinomatous and sarcomatous tissues from 10 patients diagnosed with homologous UCS (see Table 1). Separately in both tissue types in each
patient, using paired adjacent normal tissue as a contrast, we performed genome48

wide SCA and targeted point mutation profiling, using SNP DNA microarrays and
deep next-generation sequencing (NGS). We also performed whole-transcriptome
(NGS) expression profiling in these tissues (RNAseq), attempting to relate expression patterns to underlying genomic features.

Subject
0317
0609
0619
0622
0724
0819
0829
0909
1104

Age at
diagnosis
(yrs)
58
89
64
68
39
71
61
65
74

Stage at
diagnosis

Response

Carcinoma EMT
classification

Sarcoma EMT
classification

IIB
IIA
IB
IIIA
IVB
IIIB
IA
IA
IIIA

Complete response
Complete response
Complete response
Complete response
Progressive disease
—
Complete response
Complete response
Complete response

epithelial
EMT
epithelial
epithelial
—
—
epithelial
—
EMT

EMT
EMT
epithelial
EMT
—
EMT
epithelial
epithelial
EMT

Table 3.1: Patient clinical overview

3.3
3.3.1

Materials and methods
Sample collection
Samples from 10 patients diagnosed with UCS were collected at Avera McKen-

nan Hospital & University Health Center. This study was approved under the Avera McKennan Institutional Review Board (#2015.020). Subjects were consented to
the Gynecologic Specimen Bank (GSB), which includes specimen collection and genetic/genomic evaluation. We were also allowed to use de-identified samples from
deceased patients as per the Avera Institutional Review Board (approval date April
24, 2015). The three components (carcinoma, sarcoma, and normal) were identified
from corresponding pathology slides by a pathologist (RS). For this study to re49

duce additional sources of variation, patients were selected based on a confirmed
homologous uterine carcinosarcoma determination. The tissue samples were collected during surgery (resection) and were preserved in formalin fixed paraffin
embedded (FFPE) blocks. The slide was overlaid onto the FFPE block and macrodissection of an FFPE core using a punch biopsy tool (three - 1mm punches or one
3mm punch) was performed. DNA and RNA were extracted using the Qiagen
AllPrep DNA/RNA FFPE kit (Valencia, CA, USA) as per manufacturer’s protocol.

3.3.2

SNP arrays
Single nucleotide polymorphism (SNP) data was generated using the Illu-

mina Infiniumő OmniExpressExome-8 v 1.3 BeadChip array (Illumina Inc., San
Diego, CA, USA). Extracted DNA was subjected to the Infinium HD FFPE DNA
Restoration protocol prior to genotyping (Illumina Inc., San Diego, CA). Infinium
processing was carried out following the manufacturer’s instructions. Raw intensity files were analyzed in Illumina Genome Studio Genotyping Module software
(v2011.1). Cluster locations for genotype calling were imported from a vendor
supplied cluster file (HumanOmniExpressExome-8v1-2_A.egt).

3.3.3

DNA sequencing, alignment and mutation calling
Targeted deep sequencing across 174 amplicons within 26 cancer genes was

performed to assess somatic variation using the Illumina TruSight Tumor 26 Sample Preparation Kit (Illumina Inc., San Diego, CA). DNA samples were subjected
to FFPE quality control quantitative PCR (qPCR) to determine suitability for PCR
amplification relative to a non-FFPE reference sample. Amplicon based DNA sequencing libraries were pooled at a normalized concentration (4 nmol/L) and
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quantified via qPCR utilizing the KAPA Library Quantfication Kit (KAPA Biosystems, Woburn, MA) prior to sequencing on an Illumina MiSeq to a mean depth
of 6000x. FASTQ files were generated in MiSeq Reporter software v1.0.0 (Illumina Inc., San Diego, CA). To call somatic mutations, we applied the Illumina
Amplicon-DS Somatic Variant Caller. Calls in the tumor samples were deemed potential germline variants and removed if variant reads existed in the paired-normal
sample. Tumor variants with lower than 2% allele frequencies were excluded.

3.3.4

RNA sequencing, alignment and analysis
Whole transcriptome sequencing was performed to quantify gene expres-

sion. Each FFPE RNA sample was assessed for degradation on an RNA 6000 Nano
chip with a 2100 BioAnalyzer (Agilent; Santa Clara, CA). The average concentration and RNA integrity score (RIN) of the sample set averaged 678.5ng/ul and
2.24 respectively. Sequencing libraries were prepared using the TruSeq Stranded
Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina, Inc; San Diego, CA)
following the low sample procedure. Fragmentation was reduced to zero to accommodate the FFPE nature of the samples. The concentration of each library
was determined by qPCR utilizing the KAPA Library Quantification Kit for Next
Generation Sequencing (KAPA Biosystems; Woburn, MA) prior to sequencing.
Sequencing-by-synthesis (SBS) was performed on a HiSeq2500 utilizing v4 chemistry with paired-end 101-bp reads and a 6-bp index read resulting in approximately 4.2 billion paired-end (or total) reads. De-multiplexing of the raw sequence
data and FASTQ generation was carried out using bcl2fastq (v2.17) where each
sample averaged 138.4 million paired-end reads. Sequence reads were aligned
to the GENCODE version 19 transcriptome using STAR [68], resulting in 75 million reads per sample for downstream analyses. RSEM [69] was utilized for gene
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expression quantification. We removed six samples (two normal, three carcinomatous, and one sarcomatous samples) from our analyses because their alignment
rates were less than 30%. We then applied EBSeq to detect any differentially expressed genes between carcinomas and sarcomas.

3.3.5

Detection of chromosomal alterations
To profile SCAs, we applied a haplotype-aware hidden Markov model (HMM),

hapLOH, designed to detect acquired allelic imbalance, including those at low mutant cell fractions or exhibited in tumor samples of low cellularity [48]. To do so
we performed standard SNP genotype quality control procedures and estimated
haplotypes using MACH [41] in the normal samples. To increase phasing accuracy, we integrated samples from other studies with the same array platform. One
patient was removed because of a failed genotyping correlation QC step that verifies that paired carcinomas and sarcomas came from the same individual. Thus
in our genomic analyses, we have nine patients (27 samples) in total. We then applied hapLOH to each carcinomatous, sarcomatous, and normal sample with two
aberrant states, summarizing SCAs as those with maximum posterior probabilities
from the HMM exceeding 0.95 and boundaries established where posterior probabilities fell below 0.5. We took the SCA calls that were made for each sample of
a patient and then tested if these events existed in the other samples of the same
individual using the following algorithm. We applied a binomial test to assess
whether there was higher than expected phasing (utilizing the estimated germline
haplotype) within the A/B alleles having allele frequencies greater than the expected 0.5 (for a heterozygous site) within called event regions derived from other
samples of the same patient. In addition, we statistically tested whether the excessive haplotype in each sample, is the under-represented haplotype (over the same
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genomic region) of other samples from the same patient. These regions where opposite haplotypes are over-represented are deemed to be separate mutation events
which we term mirrored AI.
Downstream comparisons of the RNA-seq, DNA somatic mutation and SCA
calls, between tumor components and among patients, as well as generation of
graphical displays, were performed using R (www.r-project.org).

3.3.6

Inter-component heterogeneity
We assessed inter-component heterogeneity by quantifying differences in

genomic SCAs between UCS component samples within each patient. First, regions of the genome that exhibited component-specific AI, were identified (see the
light-blue and green regions of Figure 1A). Next, for regions where both components exhibited AI, we identified regions where paired samples had different overrepresented haplotypes, signifying putative component-specific events (see the
blue and red regions of Figure 1B). We identified these component-specific regions
by first taking event regions called by hapLOH, and then applying a binomial test
checking for inconsistency of the over-represented allele at each heterozygous site
between the paired samples over that region. Our inter-component heterogeneity
measure is then the proportion of heterozygous sites that are in component-specific
events compared to the total number of event heterozygous sites.

3.4

Results
Gene expression patterns between the carcinoma and sarcoma samples re-

vealed few differences (Supplementary Figure 1), where gene set analyses of differentially expressed genes failed to identify any component-specific aberrant cancer
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Figure 3.1: Identification of UCS somatic chromosomal alterations (SCAs) that
are shared, carcinoma-specific and sarcoma-specific. B-allele frequencies across
the genome of the carcinoma (top) and sarcoma (bottom) components of a UCS
tumor from subject 0609. The fluctuating blue line across the plot represents a posterior probability of SCAs across each sample’s genome. Dark blue dots represent
the B-allele frequencies at markers in the genome where both the carcinoma and
sarcoma components exhibit SCAs. Light blue represents portions of the genome
that have carcinoma-specific SCAs (see chr 6). Similarly, green represents portions
of the genome that have sarcoma-specific SCAs (see chr 7q). Both the carcinomaspecific and sarcoma-specific SCAs are characterized as private SCAs in downstream analyses.
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Figure 3.2: Identification of UCS mirror allelic imbalance (mirror AI) from somatic chromosomal alterations. The blue and red markers for each plot correspond to the same maternal and paternal haplotypes for the pair of samples described in Figure 3.1, identifying regions of the genome that are discrepant in
their over-represented haplotypes. This suggests that events at these regions of
the genome are independent; thus, events in these regions are re-classified from
shared to private SCAs.
pathways. An epithelial-to-mesenchymal (EMT) phenotype has previously been
associated with UCS, and more specifically with higher-degrees of sarcomatous
cells in bulk UCS tumor analyses [70]; thus, we investigated the EMT statuses in
our component samples. Through clustering of samples based on the expression
of known EMT genes (6-down regulated and 5 up-regulated genes [67]), nine samples were identified as EMT-like and seven as epithelial-like (Figure 2). EMT-like
statuses were more common in the sarcomas (5 of 8) versus carcinomas (2 of 6), although not at statistical significance. For 7 patients where both components were
successfully profiled, 5 component-pairs resulted in common EMT-like statuses.
For 2 component-pairs from patients 0317 and 0622, sample classification resulted
in discrepant EMT-like statuses, where the carcinoma components were epitheliallike and the sarcomatous components were EMT-like.
A total of 42 somatic mutations were called from the 26 cancer-gene se55

Figure 3.3: Gene expression pattern in UCS component samples based on EMT
signature genes. Samples are segregated into two groups based on the unsupervised clustering of gene expression values of EMT-associated genes.
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quencing panel, with zero to four mutations being called per carcinoma sample
and one to three mutations per sarcoma sample. Mutations in TP53 and MSH6
were the most prevalent, detected in 67% and 61% of samples respectively (Figure 3). Other recurrently mutated genes identified include FBXW7, FGFR2, KRAS,
PIK3CA, CTNNB1 and PTEN, all of which have been previously identified in gynecologic carcinosarcomas [65, 67, 71] (Figure 3). Mutations identified in the carcinomas were identical to those identified in their sarcoma counterparts with the
exception of four of the mutations identified (38 of 42). A PIK3CA E542K mutation was unique to subject 0609’s sarcoma component, and frameshift insertions
in MSH6 were identified in the sarcoma components of subject 0724 and 1104. A
frameshift deletion was also identified in the carcinoma component in the tumor
of subject 0819 and not in the corresponding sarcoma component
A mean of 89% of the genomic SCA regions identified per UCS tumor were
shared between paired carcinoma and sarcoma samples, with 5.7% and 5.8% being
unique to the carcinoma and sarcoma components respectively. The total load of
genomic SCA per sample is illustrated in the top column bar of Figure 3. The
amount of component-shared SCA is in light-gray and the component-specific
SCA is illustrated in black, which is a measure of inter-component heterogeneity.
EMT-like status was associated with advanced stage upon diagnosis in each
of the patients (Fisher’s test, p = 0.02; comparing stage I UCS versus stages IIIV). EMT status was also associated with higher degrees of inter-component heterogeneity based on the amounts of inter-component SCA differences (Wilcoxon
rank sum, p = 0.03). Further, for all three of the UCS tumors that exhibited intercomponent mutation differences that had available EMT classifications, their sarcomas were classified as EMT-like.
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Figure 3.4: An integrated view of genomic AI, mutations and gene expression
for UCS carcinoma and sarcoma components. Each column represents a UCS
sample. The samples are sorted by EMT status first (as determined by RNA-seq
clustering of EMT-specific genes) and then by decreasing amounts of private SCAs
(which is a putative measure of UCS heterogeneity equal to the proportion of the
genome that is aberrant in the corresponding sample but not in its UCS component
counterpart).
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3.5

Discussion
Modern statistical genomic approaches allow inexpensive, genome-wide

SCA profiling of even subclonal mutations. These techniques that leverage germline
haplotype information can better disentangle recurrent mutations from those which
may have arisen earlier (monoclonal origins). These techniques had not to date
been applied to UCS tumors, particularly their distinct sarcoma and carcinoma
components. We sought to further contextualize these discoveries amidst the landscape of point mutations from targeted DNA and whole-transcriptome RNA surveys from NGS.
Consistent with recent mutation-based studies, both carcinomatous and sarcomatous components exhibited similar molecular profiles, suggesting that both
components in UCS originated from a single clone. Where mutation differences
existed between components in three of the four patient tumors, the sarcoma components had the additional mutations, hinting that it may be more common for the
sarcoma to differentiate from carcinoma origins. Where inter-component heterogeneity based on SCA profiling exists, quantification of genomic differences may
provide insights into the progression of UCS and may be clinically informative.
Our results imply that higher degrees of mutational or SCA heterogeneity reflect
more advanced disease.
In addition, gene expression classification of EMT-status may provide similar insights into tumor progression. Of importance, we observed that gene expression based classification of EMT status of the carcinomatous and sarcomatous components are often discrepant; thus, in a mixed-cell population, profiling of the UCS
tumor in bulk may fail to identify an EMT-like status, indicating that componentbased profiling may be required in such a scenario.
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Clinically, a discretized stage classification has been identified as the most
important prognostic factor for patients with UCS and is used to guide treatment
decisions. Treatment approaches are stratified on whether or not advanced disease
is present or suspected based on imaging. Surgery is recommended for patients
with no evidence of metastatic disease; the treatment of women with metastatic
UCS is palliative [72]. For women with extrauterine disease limited to the peritoneum, surgical cytoreduction is recommended. Yet, these patient evaluations do
not take into account molecular features of UCS such as EMT status, although it is
well accepted in cancer research that EMT status is a measure of metastatic potential, suggesting that this measure may be clinically informative, especially in cases
where results from metastatic imaging are inconclusive. In summary, our study
proposes that profiling of carcinomas and sarcomas separately and quantification
of inter-component heterogeneity may be clinically informative, possibly enabling
a refined staging of UCS, with more effective stratification of patients for current
and future treatment modalities.
The relative rareness of UCS limits the number of subjects with available
tissue for molecular profiling and is a limitation of this study. However, the combination of DNA somatic mutation data, gene expression, and allelic imbalance
provides compelling evidence regarding the heterogeneous nature of UCS components and its relationship to the clinical disease. Future work may comprise the
study of additional patients with homologous disease and exploring differential
methylation patterns between the carcinomatous and sarcomatous components.
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Chapter 4
Discussion and future work

In this dissertation, we examined CNVs originating from both germline
transmitted de novo duplications and those somatically acquired. Although the
mechanisms that cause these CNVs differ, they can be characterized in similar
ways by describing their effects on chromosomal segments; thus, haplotype inference can substantially inform these types of analyses. Since haplotypes describe
the sequence of alleles on a single chromosome, they naturally have relevance in
problems of inference for chromosomal phenomena. We illustrated in two projects
that incorporating haplotype information in CNV analyses provides better resolution in these analyses.
In the first project, we proposed a statistical model for profiling possible
chromosomal configurations of de novo copy number duplications. We analyzed
three family based GWAS datasets, which are from craniofacial (1670 trios), autism
(748 trios), and twins (1244 trios). Our model and analyses are based on data generated from SNP microarrays, which are robust and cost-efficient. However, these
arrays do not cover all the heterozygous markers in a human genome. In fact, we
limited the minimal size of duplications in our detected results to 50 kb because of
the sparse distribution of the SNP markers in the genome. As whole genome sequencing (WGS) becomes more affordable and several consortia to generate publicly available data, we will be able to apply our model to additional samples. The
noise level may be higher in WGS compared to SNP arrays, but the higher marker
density should help to reduce the number of undeterminable events. In addition,
the long read sequencing technologies (third-generation sequencing), such as sin-
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gle molecule real time sequencing (SMRT) and nanopore sequencing, which output the DNA fragments as long as 1,000 bases, may be used as a validation method
to molecularly examine our results by querying the duplication region itself.
A novel duplication configuration, which contains both bi-allelic and triallelic duplications in the adjacent regions (complex duplication), is found in all
three datasets. We record the rate of the complex duplications at 6% among all
the de novo duplications. The complex duplications reveal the complexity of the
genomes and may explain some of the outlier events, which for example were
characterized as mosaic because of the extensive length of the mutational regions
but in fact are germline transmitted because of the presence of the genetic information in the tri-allelic region from both homologs originated in the same parent. We
propose the hypothesis of the genesis mechanism of complex duplications, which
will be very interesting to be carried forward in molecular studies.
Our model assumes that the events we analyzed are true de novo duplications, resulting in a possible overestimate of bi-allelic duplications. The false positive de novo duplications are somewhat unavoidable especially for early mutations.
One example is a mutation occurred during early embryonic cell cycle (somatic)
where the chromosomal change exist in a major lineage of the cells. When this
specific type of cells being genotyped, the mutation will be seen in 100% of the
DNAs. It is also largely affected by the quality of the data as well as the sensitivity of the CNV detection algorithms. We found more bi-allelic duplications than
tri-allelic in the datasets of autism and twins, while the bi-allelic to the tri-allelic
duplications maintains a 1-to-1 ratio in the craniofacial dataset. A potential reason
may be the differences in terms of data quality among the three datasets (Figure
A.4).
Our current MZ twin analysis finds six events - three being de novo and three
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likely somatic. We could attempt to adjust the estimation of de novo duplications
based on results from our MZ twin studies. However, the correction based on six
samples is difficult to achieve statistical significance. More MZ twins should be
analyzed. In addition, the same array platform (marker density) and DNA sources
among different datasets would potentially reduce the batch effect. Even with the
limited number of MZ twins who have de novo duplications, we are still able to
see different mutational phenomena: the germline transmitted de novo bi-allelic
duplications, the germline mosaic tri-allelic duplications, and the somatic mosaic
duplications. Our model can provide further insights into the genesis of congenital
disorders and may shed light on studying the human reproduction process, otherwise less assessable to observation, with the perspective of a population genetic
approach.
Moreover, in the report of the last phase of 1000 Genomes Project, the human genome sequencing map completed ∼ 96% of the human genome. But the
structural variations, especially the SD regions, are still a missing puzzle to the construction of the human genome [73, 74]. Indeed, the high similarities between the
SDs have made the alignment to the reference genome challenging and thus impacts many if not all genomic studies. Despite that our method is limited to only
the duplications which cannot cover all the SD-mediated copy number changes,
we can provide an orthogonal direction to analyze the duplication regions and
provide additional evidence to at least confirm a few questionable regions whether
they arose from inter-chromosomal NAHR (tri-allelic) and thus close to a segmental duplication region in the genome.
The second project, our study of UCS, were from separated carcinomatous
and sarcomatous components generated from data of multiple platforms, including whole genome SNP array, targeted DNA sequencing and whole transcriptome
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sequencing. This provided a model to more closely examine chromosomal mutations where careful consideration of haplotypes could yield additional insights.
We proposed that component-specific analyses might be more clinically informative. However, analyses from only 10 patients limited the statistical interpretation
of the results, and further patient recruitment and continued analyses should be
conducted. In addition, although the targeted DNA sequencing reached extremely
high depth of coverage for the 26 cancer-related genes, it revealed very few differences between components. Thus, mutations were ignored in our current measure of heterogeneity. Through a more comprehensive sequencing approach (such
as whole exome sequencing), we may be able to identify more mutation differences between components, which would better inform inter-component heterogeneity. Further, we used normal uterine tissue as controls that may harbor mutations themselves due to potential cancer field effects. Instead, if we used normal
blood as controls, this may improve our ability to identify true somatic mutations.
Lastly, we could collect samples from multiple regions within each component
tissue. This could serve as two purposes: One is to validate our computational approach in the detection of mirror AI; Another one is to more precisely assess tumor
heterogeneity and confirm our findings within the context of the UCS components.
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Appendix A
Appendix

A.1
A.1.1

Supplementary: de novo duplications
Extended introduction
Recurrent CNVs, resulting from the predisposing genomic architecture, have

been found in related to many congenital diseases. Unlike Mendelian diseases that
can be detected through linkage analysis, there is no inheritance pattern to follow
in diseases caused by de novo CNVs. Initially, a congenital disorder was discovered
by “phenotype-first” approach; it was documented as observations of the common
clinical features, and the similarity of the genetic changes as well as the association
between the clinical presentations and the genetic variations were discovered later
on [9]. A classical example could be William-Beuren syndrome, which was first
described by J. C. P. Williams and A. J. Beuren in 1960’s [75, 76] through observing
the same clinical features in seven patients. Then it was discovered that WilliamBeuren syndrome was caused by the deletion of the region in chromosome 7q11.23
in 1996 [77]. Thus now the diagnosis of the William-Beuren syndrome requires a
confirmatory genetic test, usually done by either microarray or fluorescent in situ
hybridization (FISH). Similar examples include Prader-Willi and Angelman syndromes caused by the 15q11-q13 deletion [78] and Velocardiofacial syndrome (also
called DiGeorge syndrome) caused by the 22q11.2 deletion [79].
The development of modern high-throughput genotyping technologies, such
as array comparative genomic hybridization (aCGH), microarray, and next generation sequencing, have rapidly promoted the discoveries of many more recurrent
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genomic disorders. For instance, autism spectrum disorder (ASD) was not traditionally considered as a recurrent genomic disorder because there are no common
recognizable clinical features and no common chromosomal rearrangement, until
several comparative studies between large cohort and control datasets [80, 81, 13,
82]. Similar examples include schizophrenia [83] and craniosynostosis [84]. Since
then, common genomic abnormalities have become a first entry to be investigated
and such “genotype-first” approach is now routine.
Initially the chromosomal abnormalities were detected by the cytogenetic
techniques such as karyotype analysis or fluorescence in situ hybridization (FISH),
when there is a common clinical phenotype presents [9]. For example, the association between the 15q11-q13 deletion and Prader-Willi and Angelman syndromes
was reported by Butler et al in 1986 [78], and the association between the 7q11 deletion and Williams-Beuren syndrome was reported by Jurado et al in 1996 [77]. The
development of modern high-throughput genotyping technologies has prompted
rapid discoveries of many more syndromes related to de novo CNVs by surveying
large cohorts as well as normal individuals [13, 15, 83]. And the associations were
difficult to detected previously by their clinical representations such as autism or
schizophrenia. Non-allelic homologous recombination (NAHR) during meiosis
are generally considered the formation mechanism behind de novo CNVs. The process results in two reciprocal products: a deletion of the affected genomic region in
one chromosome and a duplication of the same region in the second chromosome.
If the rearrangement were transmitted to next generation, it is hard to differentiate
from somatic mosaicism events, especially from the early mosaic events. Unless,
the additional information within a de novo duplication can further validate the
genesis time and origin, i.e., carrying a third haplotype that wasn’t belong to any
of the two transmitted chromosomes. Here, we focus on de novo duplication and
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aim to disentangle the haplotype structure to better understand the NAHR mechanism.

A.1.2

Parental origin inference
Our model can not only make inference about the duplication configuration

u, but can also make inference about f , the parent of duplication origin. To do so,
we need to substitute f for u in Equation (2.1) and assume equal probability of f .
Thus the inference about f becomes:

p(f = 1|b, ĥ) =

p(b|f = 1, ĥ)
p(b|f = 1, ĥ) + p(b|f = 0, ĥ)

.

(A.1)

Also by assuming i, j and u being independent and uniformly distributed, we
should be able to integrate over all the possible i, j and u to calculate the likelihood function:
p(b|f, ĥ) ∝

X X X

p(b|i, j, u, f, ĥ).

(A.2)

i=1,2 j=1,2 u=0,1

The right hand side of Equation (A.2) can also be calculated through Equation (2.3). For convenience, we will use pf 1 to represent p(f = 1|b, ĥ) in the following sections.

A.1.3

Inference about the parental origin and the duplication configuration
Furthermore, we can calculate the joint posterior probability of u and f ,

which offers information about the duplication configuration and the parental
source together. Parameters u and f can be considered independent and evenly
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distributed, thus

p(f, u|b, ĥ) = P

p(b|f, u, ĥ)
.
P
p(b|f,
u,
ĥ)
f =0,1
u=0,1

(A.3)

The computation process to determine p(f, u|b, ĥ) is similar to Equations (2.2, 2.3).
The difference here is that it only needs to integrate over the “normally” transmitted chromosomes i and j. Our model reports four numbers as the posterior
probabilities corresponding to the source of the extra copy of DNA: (1) the homologous chromosome of the transmitted paternal chromosome (u = 1, f = 1,
written as pu1,f 1 ); (2) the transmitted paternal chromosome (u = 0, f = 1, written
as pu0,f 1 ); (3) the homologous chromosome of the transmitted maternal chromosome (u = 1, f = 0, written as pu1,f 0 ); (4) the transmitted maternal chromosome
(f = 0, u = 0, written as pu0,f 0 ). These four probabilities sum to one. If one of the
four probabilities approximates to 1, the haplotype structure supports this type of
configuration, thus it will be concluded as the duplication configuration for the de
novo duplication we are examinating.

A.1.4

Configuration distribution
From the probability inferences of duplication configurations, many sam-

ples can be easily categorized as bi-allelic or tri-allelic if the pu1 is closer to 0 or 1.
For the duplications with pu1 in between 0.1 and 0.9, we considered as undeterminable because the signal is not strong enough to draw the conclusion. Figure
A.1 shows the distribution of pu1 and colored by the categories.
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Figure A.1: The inference probability distribution of all the de novo duplication.

A.1.5

Simulation

Sensitivity evaluation
To better prove our model’s performance, we simulated de novo duplications’s genotype data. Within each simulation, we randomly picked one father
and one mother from our dataset and extracted haplotype information from the
normal regions for a selected length L. Given the duplication configuration u and
the parent of origin f , we randomly selected one transmitted haplotype from each
parent and generated a “known” de novo duplication. We simulated the BAF data
for locus i (1 ≤ i ≤ L) in the pseudo-offspring as follows. For duplication genotypes AAA and BBB, the BAF values follow Normal distribution with means 0
and 1 respectively, and standard deviation σ1 . In situations where the simulated
BAF value of AAA (bi|AAA ) is less than 0 (impossible in real case), bi|AAA = −bi|AAA .
In situations where the simulated BAF value of BBB (bi|BBB ) is larger than 1 (also
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impossible in real case), bi|BBB = 2 − bi|BBB . For duplication genotypes AAB and
ABB, the BAF values follow Normal distribution with means

1
3

and

2
3

respectively,

and standard deviation σ2 .
To make sure there are enough heterozygous markers (informative markers)
within the randomly selected parental regions, if the parent where the duplicated
copy arose from has the homozygous rate larger than 90%, we removed it from
our simulation.
Since we know the duplication configuration u and the parent of origin f in
the simulation data, we can calculate the miscalculation rate. To avoid the affect of
the homozygosity of the randomly selected parental regions, if the parent where
the duplicated copy arose from has larger than 90% homozygous rate, we removed
it from our simulation. For a simulated de novo duplication, if the statistical inference û is different from the pre-defined u for 10% (|û − u| > 0.1), we considered the
estimation is inaccurate.
We first look at the sensitivity of our model in terms of duplication length.
Since we don’t have the actual offspring data, we randomly selected 20 individuals
in the real dataset and collected the BAF values from the normal diploid region,
from which we estimated the corresponding parameter q1 , q2 and σ. We set the
standard deviation of the simulation data as σ1 = 0.05 and σ2 = 0.03, which are
close to the estimated parameters we learned from the data. Then started from a
length of 20 markers, we simulated 1000 de novo duplications and calculated the
miscalculation rate. Figure (A.2) shows that for a length larger than or equal to 30
markers, our model can make accurate inferences for more than 90% of the de novo
duplications.
We then look at the sensitivity of our model in terms of the modeling parameters. The duplication length is fixed as 100 markers and data were simu70

lated with parameters σ1 = 0.025 and σ2 = 0.03. We evaluated our model’s sensitivity through a heuristic combination of parameters q1 ∈ {0.01, 0.02, ..., 0.10},
q2 ∈ {0.90, 0.91, ..., 0.99}, and σ ∈ {0.01, 0.02, ..., 0.10}. We followed the same procedure as in fixed length evaluation process (1,000 simulation run per setting). Figure A.3 shows that when the parameter space within a certain range, our model
can achieve sensitivity at 98%.

Specificity evaluation
The specificity evaluation can be achieved by applying our model to the region where there is no structural variation event, i.e., normal region. To get the
normal region, we took advantage of the CNV calling algorithm results. We excluded all the regions being called in the initial results produced by pennCNV.
These are the regions susceptible to be duplication or deletion, or showing abnormal genotype patterns such as large Log R Ratio standard deviation, etc. For
the rest of the genome region, we evaluated several metrics such as BAF deviation, LRR deviation to confirm if it fits the normal diploid genome pattern. We
randomly picked normal regions with the length ranging from 30 to 600 markers.
Then we used our model to infer the duplication configuration for each normal
region, which is treated as a de novo duplication. We found out that there are few
normal regions having the probability inference pu1 larger than 0.5. Note that we
considered pu1 > 0.9 indicates a tri-allelic duplication. The simulation shows our
model?s specificity is always larger than 97.5% if we use a very loose threshold
for pu1 at 0.5. And it also depends on the length of the region, i.e., the number of
informative markers in the region we are making inference of.
One pitfall we have for our model is that we found out that more than 95%
of the normal regions tend to have the probability inference pu1 ≈ 0, which is an
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Figure A.2: Model evaluation of duplication lengths. We simulated offspring’s
BAF data for the pseudo-duplication region from predefined haplotype structure.
All parameters other than duplication length are controlled by the simulation. We
set the simulated parameter σ1 = 0.02 and σ2 = 0.03. And we pre-assigned the
parameters in our model as close to the simulated distribution as possible. Here
we have q1 = 0.0362, q2 = 0.9566, and σ = 0.03. The duplication lengths are from
20 markers to 500 markers, adding 5 markers each time. And for each duplication length, we simulated 1,000 de novo duplications and the miscalculation rate
showing in this Figure is the percentage of mis-estimated duplications in the 1,000
simulated duplications.
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Figure A.3: Model evaluation of parametric settings. We set the duplication
length as 100 markers and simulated data with parameters σ1 = 0.025 and σ2 =
0.03. To evaluate our model’s sensitivity, we model the parameters ranging at
q1 ∈ {0.01, 0.02, ..., 0.10}, q2 ∈ {0.90, 0.91, ..., 0.99}, and σ ∈ {0.01, 0.02, ..., 0.10}.
For each combination of the parametric setting, we simulated 1,000 de novo duplications, each of which has 100 markers. We can see that when the estimated
parameters are within a certain range, our model can still achieve good sensitivity
(mostly larger than 98.5%).
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indication that this is a bi-allelic duplication. However, if we delve into the detail scenarios of the combination of the genotypes, it can explain the results. Let us
look at a simple example in which the two transmitted haplotypes from parents are
“ABAB” and “AABB” from marker 1 through 4. If the offspring inherited one copy
from each (normal diploid region), the genotypes in marker 1 to 4 should be “AA”,
“AB”, “AB”, and “BB”, which are corresponding to B Allele Frequencies around
0, 0.5, 0.5, and 1. Among these four markers, the BAFs in the two heterozygous
markers (marker 2 and 3) are against the proposed region being in duplication,
neither bi-allelic nor tri-allelic. But the two homozygous markers (marker 1 and 4)
cannot leverage in the same direction. To the contrary, both will result in high likelihood of being in a bi-allelic duplication (genotypes “AAA” and “BBB”). Simply
put, the normal region is also supported by the bi-allelic scenario.

A.1.6

Further details on samples DNA source
In the craniofacial dataset, there are 1670 trios in which the offspring DNA

are from blood samples, 328 trios with the offspring’s DNA from non-blood samples (256 buccal, 5 mouthwash, 67 saliva), and 80 trios with the offspring DNA
from blood samples but being whole-genome amplified (WGA). In the autism
dataset, there are 748 trios in which the offspring’s DNA are from blood samples,
and 319 trios in which the offspring’s DNA are from non-blood samples (236 cell
line, 4 buccal, 79 unknown). In the twin dataset, there are only 28 trios in which
the offspring DNA are from blood, the other 1216 trios having the offspring DNA
from buccal.
We have noticed that the cell line samples tend to introduce false positive
copy number variation calls such as culture-induced somatic artifacts [11, 50] and,
in our case, as the cell line grows the number of bi-allelic duplications is likely to in74
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crease. On the other hand, a tri-allelic duplication has to have the non-transmitted
homolog as the source for the extra copy of DNA in the duplication region thus
it won’t be introduced by cell line artifact unless it has already existed. Our initial results including cell line samples also supported the statement that the cell
line samples only biased our estimation for bi-allelic. In the autism dataset, we
found nine bi-allelic out of 319 non-blood sample trios (2.8%, along with one triallelic and two undeterminable). While from the 748 blood sample trios there are
only seven bi-allelic (0.9%, along with four tri-allelic, four undeterminable, and
one complex) (Supplement Figure A.5). To keep the estimate consistent for both
craniofacial and autism datasets, in our duplication configuration rate analysis, we
only reported the trios with offspring DNA from blood samples, and the analysis
for all non-blood sample trios are shown in Supplementary. The twin dataset has
its own uniqueness about the identical DNA sharing between the monozygotic
twin pairs and most of them are from buccal samples, we will discuss the results
separately.

A.2

Supplementary: UCS
EXTRA: These are short descriptions related to things we did for this manuscript

which are not currently included in our analyses. We may incorporate these analyses if helpful or in response to reviewers.
Categorization of SCAs as gains, losses, or copy-neutral loss-of-heterozygosity
(LOH) was determined by Vattathil and a novel, unpublished updated version of
hapLOH that uses a HMM with 2 forms of data emitted, BAFs and LRR (similar to
Xia).
We applied a sequencing-based version of haploh (San Lucas) to the RNA-
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Figure A.5: The duplication configuration distribution from cellline samples.
There are 11 duplications with the offspring data collected from cellline samples,
all from the autism dataset.

Figure A.6: Phasing error example. A sample from NTR dataset
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Figure A.9: Craniofacial samples duplication overlay at chromosome 7.

Figure A.10: Craniofacial samples duplication overlay at chromosome 22.
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seq data to identify chromosomal allelic imbalance differences between the two
samples that may suggest differential de-activation of chromosomes in the components. This analysis identified a subset of the events identified in the SNP arrays.
We have also analyzed TCGA UCS array data using the same hapLOH
pipeline. And we downloaded the arm-level and focal-level events reported by
TCGA from GDAC website.
Supplementary Figure 1. Differential gene expression analyses between
component types. EbSeq [85] was used to detect differentially expressed genes
between tumor and normal samples, and then between carcinoma and sarcomatous components. (A) Normal and tumor samples clearly cluster using 5,487 identified differentially expressed genes comparing normal and tumor samples. (B)
However, only 236 differentially expressed genes were identified when comparing carcinoma and sarcomatous components, resulting in poor separation of the
components when used in unsupervised clustering.
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Figure A.11: A

Figure A.12: B
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